Vaxcyte (PCVX) Other Operating Expenses (2022 - 2023)
Vaxcyte (PCVX) reported Other Operating Expenses of $75.0 million for Q4 2023, up 226.16% year-over-year from $23.0 million in Q4 2022, and up 226.16% quarter-over-quarter from $23.0 million in Q4 2022.
Vaxcyte (PCVX) Other Operating Expenses (2022 - 2023) Analysis & Trends
Vaxcyte (PCVX) has 2 years of Other Operating Expenses data on file, last reported at $75.0 million in Q4 2023.
- Other Operating Expenses for Q4 2023 came in at $75.0 million, up 226.16% year-over-year; the trailing twelve-month figure through Sep 2024 was $75.0 million (up 226.16% YoY), and the FY2023 annual result was $75.0 million, up 226.16% from the prior year.
- Other Operating Expenses rose to $75.0 million in Q4 2023 per PCVX's latest filing, from $23.0 million in the prior quarter.
- Over five years, Other Operating Expenses peaked at $75.0 million in Q4 2023 and troughed at $23.0 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Vaxcyte | 6.34 Bn | 6.34 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 75.00 Mn |
| Dec 31, 2022 | 23.00 Mn |